Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

Go back to Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
Stratcomm Media, Ltd. (NASDAQ: SMMT) Delayed: 17.59 +0.42 (2.45%)
Previous Close $17.17    52 Week High $19.75 
Open $17.36    52 Week Low $4.26 
Day High $17.62    P/E N/A 
Day Low $16.82    EPS $0.00 
Volume 5,754,954